• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Rani Therapeutics beats Street EPS estimates in Q4

March 23, 2023 By Sean Whooley

Rani TherapeuticsRani Therapeutics (Nasdaq:RANI) shares dipped on fourth-quarter results that just managed to beat the consensus EPS forecast.

Shares of RANI fell 4.2% at $5.70 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — dipped 0.6%.

The San Jose, California-based robotic pill maker posted losses of $8.8 million. That amounts to losses per share of 35¢ for the three months ended Dec. 31, 2022. Losses slid by about $3.6 million compared to the same period in 2021.

Rani Therapeutics’ losses per share landed 2¢ ahead of estimates on Wall Street. Fourth-quarter highlights included the launch of a development program for RT-111. The RT-11 features a RaniPill GO capsule containing a biosimilar of Johnson & Johnson’s Stelara (ustekinumab).

It also develops the RaniPill HC device. This can hold five times more drug payload than its first oral biologics capsule, the RaniPill GO. The company raised $73 million from its IPO in 2021.

“The past year has proven transformative for Rani, highlighted by the positive topline Phase 1 results for RT-102 in osteoporosis and the unveiling of our high-capacity capsule, the RaniPill HC,” said Talat Imran, CEO of Rani. “We also announced the preclinical development of our oral ustekinumab program, RT-111, and earlier this year partnered with Celltrion to support the advancement of that program. These achievements mark significant milestones for the company and are a testament to the hard work and dedication of the entire Rani team.”

Imran added that the company expects to initiate its first Phase 2 study in RT-102. It also aims to begin Phase 1 studies for three additional assets.

Rani declined to provide its financial outlook for 2023.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Rani Therapeutics

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS